Powder: -20°C for 3 years | In solvent: -80°C for 1 year
UA8967 is a membrane-active anti-tumor agent. Cytotoxicity studies in six pancreatic cancer cell lines, one normal human pancreatic ductal epithelial line and two colon cancer cells showed the IC50s UA8967 ranged from 12–61 μM for exposure times of 72 h. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. UA8967 is observed to affect the plasma membrane.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | UA8967 is a membrane-active anti-tumor agent. Cytotoxicity studies in six pancreatic cancer cell lines, one normal human pancreatic ductal epithelial line and two colon cancer cells showed the IC50s UA8967 ranged from 12–61 μM for exposure times of 72 h. There was also no selective inhibition of DNA, RNA or protein synthesis after exposure to UA8967. UA8967 is observed to affect the plasma membrane. |
Molecular Weight | 305.42 |
Formula | C20H23N3 |
CAS No. | 17511-50-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
UA8967 17511-50-1 UA 8967 Vivacaine UA-8967 Bupivacaine Hydrochloride inhibitor inhibit